Innovent Announces the Phase 3 ORIENT-16 Study Results Published in JAMA Evaluating Sintilimab in Combination with Chemotherapy for the First-Line Treatment of Gastric or Gastroesophageal Junction (G/GEJ) Adenocarcinoma December 6, 2023 โ 08:16
Charm of Jiangsu International Children’s Painting Exhibition was held in Paris, France July 13, 2023 โ 22:38
Crystal Pharmatech Recognized as "Best Partner" by Allorion Therapeutics for Excellent Services July 7, 2023 โ 21:00
Sirnaomics Establishes a Strategic Partnership with EDIRNA Inc., an RNA-Editing Therapeutic Company July 5, 2023 โ 23:07
An EV Assembled Within Two Hours! Gui’an Builds a Hi-tech High-end Manufacturing Base June 18, 2023 โ 12:00
Live from ASCO 2023 | Updated Data of Olverembatinib in SDH-Deficient GIST including a CBR of 93.8% Signals a Potential Clinical Breakthrough June 5, 2023 โ 11:51
Innovent Updates Phase 1b Data of IBI939 (Anti-TIGIT Monoclonal Antibody) Combined with Sintilimab in Previously Untreated PD-L1-selected NSCLC at the 2023 ASCO Annual Meeting June 4, 2023 โ 08:36
Gracell Biotechnologies Presents Updated Data of Deep and Durable Responses for FasTCAR-T GC012F in Relapsed/Refractory Multiple Myeloma at 2023 ASCO Annual Meeting June 4, 2023 โ 02:15
Innovent Announces the Second Breakthrough Therapy Designation by NMPA for Olverembatinib for the Treatment of Patients with SDH-Deficient GIST June 3, 2023 โ 07:59
CELL WORLD – Aiming at Internationalization, Starting from Regulation – The 1st Global Cell Therapy Summit and Hillgene Biopharma Anniversary Celebration Successfully Held May 29, 2023 โ 20:03
Ascentage Pharma Presents Updated Results from Multiple Clinical Studies at American Society of Clinical Oncology Annual Conference May 26, 2023 โ 10:01
Innovent Receives NMPA Breakthrough Designation for IBI351 (KRASG12C Inhibitor) as Monotherapy for Previously Treated Advanced Colorectal Carcinoma May 15, 2023 โ 08:00
Crystal Formulation Services’ GMP Manufacturing Facility Successfully Passes the Remote Audit by US Client, Marking a Key Milestone for Its International Expansion May 12, 2023 โ 21:00
The China NMPA Approves TYVYTยฎ (sintilimab injection) in Combination with Bevacizumab and Chemotherapy in Patients with EGFR-mutated Non-squamous NSCLC who Progressed after EGFR-TKI Therapy May 10, 2023 โ 08:00
The 2023 Bund Art Festival is Coming, Starting a One-stop Art Tour at the Great Yu Garden Area May 9, 2023 โ 14:54
Suzhou GenAssist Therapeutic Co.,Ltd recently announced that its first base editing product, GEN6050, has submitted a pre-IND application to the FDA and has been accepted May 6, 2023 โ 21:00
Qiming Venture Partners Nisa Leung and Duane Kuang Made the 2023 Forbes Midas List May 5, 2023 โ 21:08
Robert Walters China Salary Survey 2023: Easing of Epidemic Control: Recruitment Market Stabilises, Data Security and Compliance Talent being Key Recruitment Targets March 2, 2023 โ 14:00
Commercialization of Gene Therapy is coming soon: Neurophth Completes Patient Enrollment for Phase III clinical trial for the gene therapy treatment of LHON February 21, 2023 โ 21:30
Eluminex Biosciences Announces Completion of Initial Enrollment in Part A of the CLARITY Study Evaluating a Human Recombinant Collagen-derived (rhCIII) Biosynthetic Cornea (EB-301) February 15, 2023 โ 01:00
Celebrate the Lantern Festival and Enjoy Lanterns in the Glittering Ancient City of Taierzhuang February 11, 2023 โ 10:21
Qiming Venture Partners Backed Structure Therapeutics Successfully Debuts on Nasdaq February 4, 2023 โ 14:45
Gracell Biotechnologies Announces FDA Clearance of the IND Application for Phase 1b/2 Clinical Trial of FasTCAR-T GC012F for the Treatment of Relapsed/Refractory Multiple Myeloma February 3, 2023 โ 20:30
China’s First and Only Approved Third-Generation BCR-ABL Inhibitor Olverembatinib Included into the 2022 National Reimbursement Drug List January 19, 2023 โ 11:45
Innovent Presents Phase 1b Clinical Data of IBI188 (Anti-CD47 Monoclonal Antibody) at the 2022 American Society of Hematology Annual Meeting December 11, 2022 โ 08:00
Gracell Biotechnologies Presents Clinical Data for FasTCAR-T GC012F for High Risk, Newly Diagnosed Multiple Myeloma Demonstrating 100% Overall Response Rate December 11, 2022 โ 07:15
